Clinical Trial Update: A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD) [Phase 2]

View source ↗

Summary

A Phase 2 randomized, double-blind, placebo-controlled crossover dose-ranging study evaluated the dose response of GSK573719 in chronic obstructive pulmonary di…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• GSK573719

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 2 | Status: COMPLETED | Results posted: 2014-02-11